A
Altheia Science
A gene therapy company
About Altheia Science
Altheia Science, founded in 2017, is a biotechnology company developing cell and gene therapies for autoimmune diseases and cancer. The company was founded by two distinguished Italian scientists, Prof. Alessandra Biffi, MD, and Prof. Paolo Fiorina, MD, PhD, in collaboration with the investment firm AurorA-TT. The leadership team includes CEO and co-founder Dr. Paolo Rizzardi, who brings a blend of scientific and managerial expertise to the company.
The company's primary focus is on creating curative treatments for autoimmune disorders by targeting the underlying causes of the disease. Altheia Science engineers hematopoietic stem cells to modulate the immune system, aiming to provide long-term solutions for patients. This approach is also being explored for applications in oncology.
Altheia Science operates from its headquarters in Milan, Italy, and has a US office in New York. The company has secured $19.3 million in funding to advance its research and development efforts. Its business model revolves around the discovery, development, and eventual commercialization of its therapeutic products, targeting a market with significant unmet medical needs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Milan, Italy
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 61.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Genetics and genomics, Autoimmune, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2018 | $8.8M | $35M | Undisclosed | ↗ |
| SERIES A✓Equity / VC | Sep 2018 | $9.9M | $40M | ROTTAPHARM BIOTECH | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Altheia Science is 120 monthly website visits, down 91.4% over the last three months. Altheia Science's team declined 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
ROTTAPHARM BIOTECH
Other known investors2 additional known investors
University of Milan
University of Padua
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Altheia Science on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Altheia Science’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.